

**Supplementary Table 1. Pleiotropy and heterogeneity analyses of Two-Sample MR between cathepsins family and different histological typ**

exposure	outcome	MR-Egger intercept		MR-PRESSO global		MR-IVW			MR-Egger		
		Egger intercept	p_value	p_value	Q	Q_df	Q_pval	Q	Q_df	Q_pval	
cathepison B	Overall lung cancer	-0.002	0.619	0.841	10.268	15	0.803	10.244	14	0.744	
	Adenocarcinoma	-0.019	0.278	0.595	12.638	14	0.555	13.915	15	0.532	
	Squamous carcinoma	0.004	0.835	0.645	11.318	13	0.584	11.273	12	0.506	
	SCLC	0.059	0.261	0.084	20.612	11	0.038	18.054	10	0.054	
cathepison E	Overall lung cancer	-0.004	0.751	0.820	5.254	9	0.812	5.146	8	0.742	
	Adenocarcinoma	-0.016	0.376	0.586	7.264	9	0.610	6.386	8	0.604	
	Squamous carcinoma	-0.012	0.658	0.473	7.815	8	0.452	7.583	7	0.371	
	SCLC	-0.037	0.299	0.299	12.465	9	0.188	10.797	8	0.213	
cathepison F	Overall lung cancer	-0.014	0.320	0.515	9.209	10	0.512	8.100	9	0.524	
	Adenocarcinoma	-0.026	0.284	0.173	15.529	10	0.114	13.573	9	0.138	
	Squamous carcinoma	-0.005	0.816	0.701	7.676	10	0.660	7.619	9	0.573	
	SCLC	-0.041	0.264	0.667	7.502	10	0.677	6.086	9	0.731	
cathepison G	Overall lung cancer	-0.001	0.967	0.309	12.134	10	0.276	12.131	9	0.206	
	Adenocarcinoma	-0.019	0.366	0.750	6.742	10	0.750	5.837	9	0.756	
	Squamous carcinoma	0.003	0.908	0.399	9.894	9	0.359	9.876	8	0.274	
	SCLC	0.021	0.674	0.074	17.291	10	0.068	16.936	9	0.050	
cathepison H	Overall lung cancer	-0.004	0.702	0.270	15.432	9	0.080	15.134	8	0.057	
	Adenocarcinoma	-0.007	0.603	0.433	10.420	9	0.318	10.052	8	0.261	
	Squamous carcinoma	0.010	0.538	0.347	13.054	10	0.221	12.485	9	0.187	
	SCLC	0.021	0.421	0.430	7.676	8	0.466	6.945	7	0.435	
cathepison L2	Overall lung cancer	-0.022	0.169	0.156	15.009	10	0.132	12.026	9	0.212	
	Adenocarcinoma	-0.010	0.630	0.452	9.263	9	0.413	8.982	8	0.344	
	Squamous carcinoma	0.003	0.931	0.072	17.830	10	0.058	17.814	9	0.037	
	SCLC	-0.015	0.663	0.884	3.349	8	0.911	3.143	7	0.871	
cathepison O	Overall lung cancer	0.016	0.227	0.799	6.806	10	0.744	5.127	9	0.823	
	Adenocarcinoma	0.023	0.215	0.871	5.882	10	0.825	4.105	9	0.904	
	Squamous carcinoma	-0.001	0.975	0.855	6.322	10	0.788	6.321	9	0.707	
	SCLC	0.013	0.804	0.212	8.970	7	0.255	8.871	6	0.181	
cathepison S	Overall lung cancer	0.019	0.022	0.074	30.317	19	0.048	22.495	18	0.211	
	Adenocarcinoma	0.018	0.066	0.211	24.987	20	0.202	20.805	19	0.348	
	Squamous carcinoma	0.023	0.049	0.134	29.214	22	0.139	24.204	21	0.283	
	SCLC	0.025	0.141	0.777	14.462	19	0.756	12.087	18	0.843	
cathepison Z	Overall lung cancer	0.025	0.141	0.757	14.462	19	0.756	12.087	18	0.843	
	Adenocarcinoma	0.025	0.141	0.763	14.462	19	0.756	12.087	18	0.843	
	Squamous carcinoma	0.025	0.141	0.766	14.462	19	0.756	12.087	18	0.843	
	SCLC	0.025	0.141	0.760	14.462	19	0.756	12.087	18	0.843	

Supplementary Table 2. The results of reverse MR analysis of different histological of lung cancer and cathepsins family

exposure	outcome	nsnp	Inverse variance weighted				MR-Egger				Weighted median				MR-Egger intercept				MR-PRESSO global				MR-IVW			
			p_value	OR	95% OR	p_value	OR	95% OR	p_value	OR	95% OR	Egger intercept	p_value	p_value	Q	Q_df	Q_pval	Q	Q_df	Q_pval	Q	Q_df	Q_pval			
Overall lung cancer	Cathepsin B	15	0.352	1.074	0.924-1.278	0.312	1.255	0.822-1.916	0.373	1.101	0.891-1.361	-0.018	0.454	0.644	11.340	14	0.659	10.743	13	0.632						
	Cathepsin E	15	0.502	1.058	0.897-1.247	0.600	1.141	0.705-1.846	0.554	1.070	0.860-1.337	-0.009	0.747	0.262	16.959	14	0.258	16.819	13	0.208						
	Cathepsin F	15	0.504	0.948	0.811-1.108	0.554	0.868	0.551-1.369	0.367	0.907	0.731-1.122	0.010	0.692	0.360	15.243	14	0.362	15.053	13	0.304						
	Cathepsin G	15	0.747	1.025	0.880-1.194	0.427	1.201	0.775-1.863	0.710	1.039	0.848-1.272	-0.018	0.463	0.443	14.572	14	0.408	13.957	13	0.377						
	Cathepsin H	15	0.447	1.107	0.852-1.439	0.789	1.114	0.515-2.408	0.953	1.006	0.813-1.245	-0.001	0.988	0.063	43.145	14	0.000	43.144	13	0.000						
	Cathepsin L2	15	0.557	0.955	0.819-1.113	0.233	0.760	0.494-1.169	0.873	0.983	0.802-1.210	0.026	0.286	0.415	14.744	14	0.396	13.462	13	0.413						
	Cathepsin O	15	0.226	1.110	0.937-1.316	0.326	1.291	0.790-2.108	0.460	1.082	0.877-1.336	-0.017	0.532	0.236	18.003	14	0.207	17.449	13	0.180						
	Cathepsin S	15	0.325	1.078	0.928-1.252	0.520	0.867	0.568-1.324	0.422	1.082	0.892-1.313	0.025	0.301	0.981	5.112	14	0.984	3.950	13	0.992						
	Cathepsin Z	15	0.191	1.117	0.947-1.317	0.365	0.807	0.516-1.263	0.284	1.121	0.909-1.383	0.037	0.152	0.255	17.102	14	0.251	14.521	13	0.338						
	Cathepsin B	14	0.763	0.979	0.854-1.123	0.536	1.169	0.724-1.888	0.322	0.914	0.765-1.092	-0.024	0.464	0.243	16.042	13	0.247	15.312	12	0.225						
Adenocarcinoma	Cathepsin E	14	0.255	1.074	0.950-1.215	0.496	1.164	0.761-1.780	0.150	1.131	0.956-1.338	-0.011	0.705	0.617	10.781	13	0.629	10.631	12	0.561						
	Cathepsin F	14	0.495	1.049	0.914-1.205	0.967	1.011	0.616-1.659	0.967	1.076	0.908-1.275	0.005	0.880	0.250	16.352	13	0.231	16.319	12	0.177						
	Cathepsin G	14	0.595	1.034	0.914-1.170	0.158	1.385	0.906-2.118	0.281	1.089	0.933-1.270	-0.040	0.183	0.712	9.705	13	0.718	7.712	12	0.807						
	Cathepsin H	14	0.598	1.062	0.848-1.331	0.476	0.746	0.342-1.627	0.800	0.977	0.817-1.169	0.048	0.372	0.142	43.402	13	0.000	40.497	12	0.000						
	Cathepsin L2	14	0.184	0.920	0.813-1.040	0.131	0.704	0.461-1.076	0.579	0.954	0.806-1.128	0.037	0.221	0.847	7.529	13	0.873	5.863	12	0.923						
	Cathepsin O	14	0.731	0.979	0.865-1.107	0.117	0.693	0.454-1.060	0.970	1.003	0.843-1.195	0.047	0.122	0.417	12.171	13	0.514	9.406	12	0.668						
	Cathepsin S	14	0.466	1.051	0.920-1.200	0.691	1.103	0.687-1.773	0.487	1.059	0.901-1.245	-0.007	0.836	0.327	12.171	13	0.514	9.406	12	0.668						
Squamous carcinoma	Cathepsin Z	14	0.328	1.078	0.928-1.251	0.260	0.745	0.456-1.215	0.546	1.057	0.884-1.263	0.051	0.148	0.125	12.171	13	0.514	9.406	12	0.668						
	Cathepsin B	6	0.033	1.189	1.014-1.395	0.438	1.264	0.741-2.156	0.038	1.224	1.011-1.481	-0.011	0.826	0.804	2.523	5	0.773	2.468	4	0.650						
	Cathepsin E	6	0.763	1.032	0.843-1.263	0.325	0.694	0.366-1.315	0.640	1.055	0.842-1.323	0.074	0.272	0.172	8.065	5	0.153	5.738	4	0.220						
	Cathepsin F	6	0.437	0.917	0.737-1.141	0.279	0.630	0.306-1.300	0.037	0.789	0.631-0.986	0.070	0.347	0.118	9.431	5	0.093	7.352	4	0.118						
	Cathepsin G	6	0.870	1.015	0.846-1.219	0.470	1.296	0.685-2.450	0.967	0.996	0.813-1.220	-0.045	0.476	0.286	6.590	5	0.253	5.708	4	0.222						
	Cathepsin H	6	0.758	0.975	0.832-1.144	0.979	0.992	0.582-1.693	0.601	0.950	0.782-1.153	-0.003	0.950	0.982	0.651	5	0.986	0.647	4	0.958						
	Cathepsin L2	6	0.146	0.882	0.744-1.045	0.136	0.602	0.353-1.027	0.635	0.950	0.767-1.176	0.071	0.216	0.350	5.664	5	0.340	3.511	4	0.476						
	Cathepsin O	6	0.964	1.004	0.842-1.197	0.566	0.820	0.439-1.530	0.979	1.003	0.805-1.250	0.038	0.541	0.307	6.072	5	0.299	5.464	4	0.243						
SCLC	Cathepsin S	6	0.678	0.967	0.824-1.134	0.640	1.147	0.673-1.956	0.916	1.010	0.834-1.223	-0.032	0.546	0.585	3.935	5	0.559	3.502	4	0.478						
	Cathepsin Z	6	0.798	0.970	0.770-1.222	0.908	0.947	0.399-2.250	0.512	0.926	0.736-1.165	0.004	0.957	0.082	10.524	5	0.062	10.515	4	0.033						
	Cathepsin B	26	0.641	1.017	0.948-1.091	0.156	1.115	0.964-1.291	0.965	1.002	0.914-1.099	-0.024	0.173	0.293	28.358	25	0.292	26.203	24	0.343						
	Cathepsin E	26	0.841	1.007	0.942-1.075	0.516	1.048	0.911-1.205	0.345	1.049	0.950-1.157	-0.010	0.528	0.581	23.060	25	0.5									

**Supplementary Table 3.** The results of multivariable MR analysis between cathepsins family and lung cancer risk.